PMID- 36441192
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 6
DP  - 2023 Jun
TI  - Treatment options for unresectable hepatocellular carcinoma with hepatitis virus 
      infection following sorafenib failure.
PG  - 1395-1403
LID - 10.1007/s00262-022-03324-z [doi]
AB  - BACKGROUND: Currently, there are a few treatment options for unresectable 
      hepatocellular carcinoma (HCC) after progression following sorafenib (SOR) 
      therapy, but with limited benefit. The purpose of this study was to investigate 
      the efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with immune 
      checkpoint inhibitors (ICIs) as second-line treatment. METHODS: From May 2018 to 
      May 2021, a total of 93 HCCs who failed SOR treatment were included in this study 
      and divided into TKI group (n = 37) and TKI-ICI group (n = 56). Overall survival 
      (OS), progression-free survival (PFS), objective response rate (ORR), disease 
      control rate (DCR) and safety were estimated among the two groups. In addition, 
      univariate and multivariate Cox regression analyses were performed for OS and PFS 
      to identify possible prognostic factors. RESULTS: With a median follow-up time of 
      13.7 months, the median age of patients was 56 (range, 50-64) years and most were 
      male. All of the patients were hepatitis virus-related HCC. Both median OS 
      (7.63 months vs 19.23 months, P < 0.001) and median PFS (2.97 months vs 
      8.63 months, P < 0.001) were significantly improved in the TKI-ICI group compared 
      to the TKI group. A significant increase in DCR was demonstrated in the TKI-ICI 
      group compared to the TKI group (83.9% vs 45.9%, P = 0.0003), although no 
      significant difference in ORR was reported (21.4% vs 8.1%, P = 0.1552). 
      Multivariate Cox regression analysis of OS and PFS revealed that second-line 
      regimen was an independent protective factor affecting death and progression in 
      HCCs after SOR failure. In addition, Child-Pugh B7 was an independent risk factor 
      of OS. Finally, there was no significant difference in the incidence of any grade 
      or grade 3/4 adverse events (AEs) between the two groups, and no 
      treatment-related deaths were observed. CONCLUSION: This real-world study 
      suggests that the combination of TKIs and ICIs benefits more than mono-TKIs and 
      is well tolerated in HCCs with hepatitis virus infection after SOR failure.
CI  - (c) 2022. The Author(s).
FAU - Li, Xiaomi
AU  - Li X
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, 100015, China.
FAU - Ding, Xiaoyan
AU  - Ding X
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, 100015, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, 100015, China. vision988@126.com.
FAU - Chen, Jinglong
AU  - Chen J
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, 100015, China. cjl6412@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20221128
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Female
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Sorafenib/therapeutic use
MH  - *Liver Neoplasms/drug therapy
MH  - Hepatitis Viruses
MH  - Immune Checkpoint Inhibitors
PMC - PMC10198937
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Immune checkpoint inhibitor
OT  - Second-line treatment
OT  - Sorafenib
OT  - Tyrosine kinase inhibitor
COIS- All authors declare no conflicts of interest.
EDAT- 2022/11/29 06:00
MHDA- 2023/05/22 06:43
PMCR- 2022/11/28
CRDT- 2022/11/28 11:13
PHST- 2022/09/02 00:00 [received]
PHST- 2022/11/01 00:00 [accepted]
PHST- 2023/05/22 06:43 [medline]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/11/28 11:13 [entrez]
PHST- 2022/11/28 00:00 [pmc-release]
AID - 10.1007/s00262-022-03324-z [pii]
AID - 3324 [pii]
AID - 10.1007/s00262-022-03324-z [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Jun;72(6):1395-1403. doi: 
      10.1007/s00262-022-03324-z. Epub 2022 Nov 28.